Cagrilintide monograph

Cagrilintide Monograph

^[1]

This page preserves the structured raw monograph for TroponinIQ Base under the shared content policy. The content is factual reference material; it is not a production prompt or constant update. No Production target: directive was present in the source.

Curation Summary

• Class: Long-acting amylin analog peptide; investigational anti-obesity agent
• Legal/regulatory status: FDA: not established as an approved product in the sources reviewed; no cagrilintide-specific Orange Book entry was identified in the material accessed. Controlled status: not established as a controlled substance in the sources reviewed. WADA: cagrilintide was not explicitly named on the extracted WADA Prohibited List page, and the extracted page did not expose a clear category ruling; because it is an investigational peptide for weight control, athletes should treat it as potentially anti-doping sensitive and verify against the current full list before use. Research-chemical caveat: any marketplace product sold as cagrilintide outside a regulated clinical supply chain should be treated as research use only and quality uncertain.
• Routing: module 03 knowledge for mechanism, clinical/performance context, legal status, safety, and FAQ retrieval.
• Source hash: db2fcb49553828799223528b174dc8340b887598543d52658b0c1e9993f08961

Overview Extract

Cagrilintide is an investigational long-acting amylin analog developed for weight management and studied both as monotherapy and in combination with semaglutide (CagriSema). Current human data support meaningful appetite/weight reduction, but the evidence base is still limited and the drug is not established as an approved obesity therapy. Clinical utility is mainly in obesity/metabolic research, not bodybuilding performance.

Use-Case Anchors

• Primary goals: Chronic weight management / obesity treatment research; appetite reduction; support for caloric restriction; studied as part of CagriSema to amplify weight loss beyond semaglutide alone.

Safety / Legal Anchors

• Common side effects: Gastrointestinal adverse effects are the main issue in available human data, especially nausea, vomiting, constipation, and related GI intolerance when cagrilintide is used in CagriSema programs. The meta-analysis found GI adverse events were more frequent than with semaglutide/placebo (RR 1.32).

FAQ Anchors

• Q: Is cagrilintide the same as semaglutide?

Source Text

Cagrilintide

Overview

Cagrilintide is an investigational long-acting amylin analog developed for weight management and studied both as monotherapy and in combination with semaglutide (CagriSema). Current human data support meaningful appetite/weight reduction, but the evidence base is still limited and the drug is not established as an approved obesity therapy. Clinical utility is mainly in obesity/metabolic research, not bodybuilding performance.

Pharmacokinetics & Mechanism

• Class: Long-acting amylin analog peptide; investigational anti-obesity agent
• Mechanism of action: Cagrilintide is an amylin receptor agonist analog designed to reduce energy intake by increasing satiety and slowing gastric emptying, which lowers appetite and supports weight loss. Human outcome data are largely from obesity trials and combination-therapy studies rather than from an approved-label package insert, so detailed mechanistic labeling remains investigational.
• Target(s): Amylin receptor signaling pathways; likely amylin receptor complexes involving calcitonin receptor with receptor activity-modifying proteins (RAMPs). It is not a GLP-1 receptor agonist itself, but it is commonly paired with semaglutide in CagriSema.
• Route(s) of administration: Subcutaneous injection only in the studied clinical programs.
• Onset: Not well established in humans; appetite suppression is expected after subcutaneous dosing, but precise onset timing is not clearly established in the authoritative sources reviewed.
• Half-life: Not well established from the sources reviewed. ClinicalTrials.gov identifies ongoing PK studies of cagrilintide B and D with steady-state PK endpoints, but the extracted registry text did not provide a terminal half-life value. If community sources claim a specific weekly half-life, treat that as unverified until confirmed in a peer-reviewed PK publication.
• Metabolism / clearance: Not well established in the sources reviewed. Human clearance/metabolic pathways were not specified in the authoritative sources accessed here; current registry text only confirms that steady-state exposure and apparent clearance are being measured in ongoing studies.

Use-Cases & Dosing Strategies

• Primary goals: Chronic weight management / obesity treatment research; appetite reduction; support for caloric restriction; studied as part of CagriSema to amplify weight loss beyond semaglutide alone.
• Typical protocols: Clinical/trial: Cagrilintide has been studied as subcutaneous once-weekly dosing in obesity trials, including 5-week PK comparisons of cagrilintide B vs D in NCT07605052 and combination use in CagriSema trials. Community/anecdotal: Not well established and not appropriate to treat as clinical dosing; internet/vendor protocols vary widely and should not be treated as reliable medical guidance.
• Cycle length: Clinical studies commonly use multi-week to multi-month treatment periods; the cited PK registry study used 5 weekly doses over about 14 weeks total. No standard bodybuilding "cycle" is established.
• Common stacks: Most commonly stacked with semaglutide as CagriSema in obesity trials. No evidence-based bodybuilding stack is established; any pairing with other fat-loss agents is anecdotal and not validated by human outcomes.
• Reconstitution / handling (peptides): Not well established from authoritative human sources reviewed. As a peptide injection, handling should follow manufacturer/trial instructions; do not assume stability, concentration, or dilution rules from unofficial sources.
• Notes: Studied subcutaneously and weekly in trials. Do not extrapolate bodybuilding microdosing or undocumented vial reconstitution schemes into a coaching knowledge base as fact; there is no approved label dosing to rely on. If discussing community use, clearly label it as anecdotal and unverified.

Clinical vs. community/anecdotal labeling is noted inline above. Community dosing is not established fact.

Side Effects & Safety / Legal

• Common side effects: Gastrointestinal adverse effects are the main issue in available human data, especially nausea, vomiting, constipation, and related GI intolerance when cagrilintide is used in CagriSema programs. The meta-analysis found GI adverse events were more frequent than with semaglutide/placebo (RR 1.32).
• Serious / less common: Serious adverse effects are not well characterized for standalone cagrilintide in publicly available authoritative sources reviewed here. In obesity trials of the combination, serious adverse events were not highlighted as a dominant issue in the abstract-level evidence, but longer-term safety remains insufficiently established.
• Contraindications: Not well established as a cagrilintide-specific label because there is no approved public prescribing label. Practical caution is warranted in patients with significant GI disease, dehydration risk, prior intolerance to incretin-like weight-loss agents, gallbladder disease risk, or when combining with other agents that worsen nausea or delay gastric emptying.
• Monitoring: Weight, BMI, waist circumference, resting blood pressure, heart rate, hydration status, GI tolerance, and adverse-event tracking are the core practical markers. In higher-risk users, consider glucose/A1c and basic chemistries if vomiting or reduced intake is significant; formal cagrilintide-specific lab monitoring standards are not established.
• Legal / regulatory status: FDA: not established as an approved product in the sources reviewed; no cagrilintide-specific Orange Book entry was identified in the material accessed. Controlled status: not established as a controlled substance in the sources reviewed. WADA: cagrilintide was not explicitly named on the extracted WADA Prohibited List page, and the extracted page did not expose a clear category ruling; because it is an investigational peptide for weight control, athletes should treat it as potentially anti-doping sensitive and verify against the current full list before use. Research-chemical caveat: any marketplace product sold as cagrilintide outside a regulated clinical supply chain should be treated as research use only and quality uncertain.

Chatbot FAQ

Q: Is cagrilintide the same as semaglutide? A: No. Cagrilintide is an amylin analog; semaglutide is a GLP-1 receptor agonist. They get paired in CagriSema, but they are different drugs with different targets.

Q: Does cagrilintide have a standard bodybuilding dose? A: No. There is no validated bodybuilding dose. The human data are from obesity studies, mainly weekly subcutaneous trial dosing, not performance use.

Q: How long does cagrilintide stay active? A: Not well established from the sources reviewed here. Ongoing PK studies are measuring steady-state half-life and clearance, but I would not quote a precise number without a peer-reviewed PK paper or official product monograph.

Q: What side effects matter most? A: GI problems are the main issue: nausea, vomiting, constipation, and reduced appetite that can overshoot into poor intake. If those show up hard, the plan is usually dose tolerance, not bravado.

Q: Is it WADA-banned? A: The extracted WADA page did not explicitly name cagrilintide, so I cannot claim a definitive category from that page alone. For athletes, that means verify against the live prohibited list before touching it.

Q: Is cagrilintide approved by the FDA? A: Not in the sources reviewed here. I did not find an FDA-approved cagrilintide product or Orange Book entry, so treat it as investigational unless a new approval is documented.

Sources

• CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity — CagriSema combines semaglutide with cagrilintide; four RCTs (n=4,419) found greater weight loss vs semaglutide/placebo and more GI adverse events (RR 1.32).
• A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight — Cagrilintide B and D are being compared as subcutaneous once-weekly injections for 5 weeks in a ~14-week study; PK endpoints include AUCss and Cmax,ss, with half-life/clearance not stated on the registry page.
• Prohibited List | World Anti Doping Agency - WADA — Cagrilintide was not explicitly named in the extracted page content; the extracted page states the 2026 list went into effect on 1 January 2026.
• [Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)](FDA Orange Book) — FDA Orange Book page is general; it did not identify cagrilintide as an approved product in the extracted content, so approval status remains unconfirmed from this source.
• Neues Mittel Cagrilintid boostert Semaglutid — Secondary PubMed citation confirming cagrilintide is discussed in relation to boosting semaglutide, but the page had no abstract and adds little beyond topical relevance.

---

Data quality: Thin-to-moderate, still experimental. Human efficacy data are decent for obesity outcomes in combination therapy, but standalone PK, half-life, metabolism, and official dosing are not well established in the sources reviewed. WADA and regulatory status are incomplete in the extracted pages, so those fields should be treated as cautiously verified rather than definitive.